Department of Respiratory Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
Division of Pulmonary and Critical Care, Miller School of Medicine, University of Miami, Miami, Florida.
Am J Respir Crit Care Med. 2023 Aug 15;208(4):442-450. doi: 10.1164/rccm.202302-0289OC.
Chronic obstructive pulmonary disease (COPD) is a prevalent and burdensome condition in low- and middle-income countries (LMICs). Challenges to better care include more effective diagnosis and access to affordable interventions. There are no previous reports describing therapeutic needs of populations with COPD in LMICs who were identified through screening. To describe unmet therapeutic need in screening-detected COPD in LMIC settings. We compared interventions recommended by the international Global Initiative for Chronic Obstructive Lung Disease COPD strategy document, with that received in 1,000 people with COPD identified by population screening at three LMIC sites in Nepal, Peru, and Uganda. We calculated costs using data on the availability and affordability of medicines. The greatest unmet need for nonpharmacological interventions was for education and vaccinations (applicable to all), pulmonary rehabilitation (49%), smoking cessation (30%), and advice on biomass smoke exposure (26%). Ninety-five percent of the cases were previously undiagnosed, and few were receiving therapy (4.5% had short-acting β-agonists). Only three of 47 people (6%) with a previous COPD diagnosis had access to drugs consistent with recommendations. None of those with more severe COPD were accessing appropriate maintenance inhalers. Even when available, maintenance treatments were unaffordable, with 30 days of treatment costing more than a low-skilled worker's daily average wage. We found a significant missed opportunity to reduce the burden of COPD in LMIC settings, with most cases undiagnosed. Although there is unmet need in developing novel therapies, in LMICs where the burden is greatest, better diagnosis combined with access to affordable interventions could translate to immediate benefit.
慢性阻塞性肺疾病(COPD)在中低收入国家(LMICs)中较为普遍且负担沉重。改善治疗的挑战包括更有效的诊断和获得负担得起的干预措施。没有以前的报告描述通过筛查确定的中低收入国家 COPD 人群的治疗需求。描述中低收入国家中通过筛查确定的 COPD 人群的未满足治疗需求。我们比较了国际慢性阻塞性肺病全球倡议(GOLD)COPD 策略文件推荐的干预措施与在尼泊尔、秘鲁和乌干达三个中低收入国家进行人群筛查确定的 1000 名 COPD 患者所接受的干预措施。我们使用关于药物可获得性和可负担性的数据计算了成本。非药物干预措施中最未满足的需求是教育和疫苗接种(适用于所有人)、肺康复(49%)、戒烟(30%)和关于生物量烟雾暴露的建议(26%)。95%的病例以前未被诊断,很少有患者接受治疗(4.5%使用短效β激动剂)。仅有 47 名(6%)以前诊断为 COPD 的患者获得了符合建议的药物。没有严重 COPD 的患者获得适当的维持性吸入器。即使有药物可用,维持治疗也负担不起,30 天的治疗费用超过了低技能工人的日平均工资。我们发现,在中低收入国家环境中,减轻 COPD 负担的机会明显被忽视,大多数病例未被诊断。虽然在开发新疗法方面存在未满足的需求,但在负担最重的中低收入国家,更好的诊断加上获得负担得起的干预措施可能会带来立竿见影的好处。